The most prevalent actionable alterations were in PI3K signaling pathway, especially for PIK3CA and PTEN. A recent study also demonstrated the high prevalence of PIK3CA alterations in cervical carcinoma patients with 31.30% altered samples, suggesting the promising targeted therapy with related PI3K or mTOR inhibitor (27). This evidence concerns the gene MTOR and cervical carcinoma.